Milestone Achievement for Moroccan Pharmaceuticals
In a significant development for the Moroccan pharmaceutical sector, Galenica has successfully dispatched its first batch of medicines to Russia, collaborating with Asia Pharm Group. This shipment represents a pivotal entry for Galenica into the expansive market of the Eurasian Economic Union (EAEU), marking a new chapter in international trade for Moroccan pharmaceuticals. As per the information provided by Russia's trade representation in Morocco, this milestone is not just a commercial venture; it signifies the strengthening ties between Morocco and Russia in the realm of pharmaceuticals.
Expanding Horizons for Moroccan Medicine
Galenica has previously secured Good Manufacturing Practice (GMP) certification and EAC marketing authorizations, vital prerequisites for the distribution of its medicines within the EAEU. Alexey Andreev, the trade representative of Russia in Morocco, highlighted the importance of this development, stating that the burgeoning pharmaceutical industry in Morocco is paving the way for enhanced bilateral cooperation. He emphasized that beyond the export of Russian medicines and initiatives to localize their production in Morocco, there are now conducive conditions for Moroccan pharmaceutical products to penetrate the EAEU market. Notably, Galenica has emerged as the first Moroccan pharmaceutical firm authorized to market its products across this economic bloc. The range of products already available in Russia includes treatments for gastrointestinal disorders, medications for cold and flu, and various other pharmaceutical offerings.
As reported by en.yabiladi.com.
